What The Study Did: In this study of more than 500,000 patients with COVID-19, those with cancer who received anticancer treatment within three months before COVID-19 diagnosis had an increased risk of death, intensive care unit admission and hospitalization, and that patients without recent cancer treatment had similar or better outcomes than patients without cancer.
Authors: Sharon H. Giordano, M.D., M.P.H., of the University of Texas MD Anderson Cancer Center in Houston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2021.5148)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2021.5148?guestAccessKey=f51f92f4-9ae3-44f9-a1b1-659a3d763658&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102821
JAMA Oncology